Buprenorphine for probationers and parolees: Bridging the gap into treatment

丁丙诺啡用于缓刑犯和假释犯：缩小治疗差距

• 批准号: 9898338
• 负责人: Michael Scott Gordon
• 金额: $ 62.84万
• 依托单位: FRIENDS RESEARCH INSTITUTE, INC.
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-07-15 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9898338
• 关键词: Adult; Area; Awareness; Baltimore; Buprenorphine; Caring; Cities; Communities; Counseling; Criminal Justice; Devices; Drug usage; Effectiveness; Frequencies; Funding; Gender; HIV risk; Imprisonment; Individual; Intake; Intervention; Intravenous; Link; Location; Medical; Mental Health; Methadone; Modeling; National Institute of Drug Abuse; Needles; Opioid; Participant; Patients; Pharmaceutical Preparations; Pharmacotherapy; Pilot Projects; Placebos; Population; Public Health; Publishing; Quality of life; Randomized; Randomized Controlled Trials; Reporting; Research; Risk Behaviors; Safety; Sex Behavior; Site; Supervision; Surveys; Test Result; United States; Urine; Waiting Lists; Woman; buprenorphine treatment; community setting; criminal behavior; design; effectiveness evaluation; heroin overdose; heroin use; high risk population; illicit opioid; innovation; men; methadone treatment; opioid agonist therapy; opioid use; opioid use disorder; outpatient programs; overdose prevention; parole; parolee; patient population; physical conditioning; prescription opioid misuse; probation; probationer; programs; reincarceration; relative effectiveness; scale up; treatment as usual; treatment program; treatment services

ABSTRACT This proposed five-year study will evaluate the effectiveness of the administration of buprenorphine bridge treatment (BBT) to probationers and parolees compared to treatment as usual (TAU), which consists of referral to a community buprenorphine treatment program. Project implementation will occur at Guilford Avenue, the primary intake unit for Baltimore City Community Supervision (Probation and Parole). The proposed study is a parallel two-group randomized controlled trial in which 160 men and 160 women with OUD on community supervision in Baltimore will be randomly assigned within community supervision status (probation or parole) and gender to one of two treatment conditions: (1) Buprenorphine Bridge Treatment (BBT): Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment; or (2) Treatment as Usual (TAU): Participants will receive a referral to buprenorphine treatment in the community. Both conditions will receive information on overdose prevention. Participants will be assessed at baseline, and 1, 2, 3, 6, and 12 months post-intake using a comprehensive assessment battery. The Primary Aim: To compare the relative effectiveness of BBT to TAU in terms of: (a) illicit opioid urine test results. The Secondary Aim: To examine the extent to which BBT is superior to TAU in terms of: (b) number of days receiving opioid treatment; (c) number of days using illicit opioids; (d) quality of life (i. physical health; ii. mental health); (e) HIV risk behaviors (i. sexual behavior; ii. needle use or sharing); (f) criminal activity; (g) re-arrest; and (h) re-incarceration. The proposed study is significant because the large number of probationers/parolees with OUD have limited access to an efficacious treatment, buprenorphine pharmacotherapy. The proposed study is innovative because it would be the first trial in the US assessing the effectiveness of interim buprenorphine initiated at a community supervision office compared to referral to a community treatment program. The public health impact would be widespread, as this model of care could be scaled-up throughout many areas of the US with criminal justice populations with high rates of OUD.

抽象的 这项拟议的五年研究将评估管理的有效性 缓刑犯和假释犯的丁丙诺啡桥接治疗 (BBT) 与以下治疗相比 通常（TAU），包括转介至社区丁丙诺啡治疗计划。 项目实施将在巴尔的摩市的主要入口单元吉尔福德大道进行 社区监督（缓刑和假释）。拟议的研究是一项平行两组 随机对照试验，其中 160 名患有 OUD 的男性和 160 名女性参加了社区活动 巴尔的摩的监督将在社区监督状态内随机分配 （缓刑或假释）和性别符合两种治疗条件之一：(1) 丁丙诺啡桥 治疗 (BBT)：参与者将使用 MedicaSafe 开始丁丙诺啡药物治疗 在社区现场摄入后立即使用丁丙诺啡分配装置 监督办公室并继续进行此类治疗，直至他们转入社区 丁丙诺啡治疗； (2) 照常治疗 (TAU)：参与者将收到转诊至 社区丁丙诺啡治疗。这两种情况都会收到有关服药过量的信息 预防。参与者将在基线以及摄入后 1、2、3、6 和 12 个月进行评估 使用综合评估电池。主要目的：比较相对 BBT 对 TAU 的有效性体现在： (a) 非法阿片类药物尿液检测结果。次要目标： 检验 BBT 在以下方面优于 TAU 的程度： (b) 接收天数 阿片类药物治疗； (c) 使用非法阿片类药物的天数； (d) 生活质量（i. 身体健康；ii. 心理健康）； (e) 艾滋病毒危险行为（i. 性行为；ii. 使用或共用针头）； (f) 刑事犯罪 活动; (g) 再次逮捕； (h) 重新监禁。拟议的研究意义重大，因为大量 患有 OUD 的缓刑犯/假释犯获得有效治疗的机会有限， 丁丙诺啡药物治疗。拟议的研究具有创新性，因为它将是第一个 美国进行的一项试验评估了在社区发起的临时丁丙诺啡的有效性 监督办公室与转介社区治疗计划相比。公共卫生 影响将是广泛的，因为这种护理模式可以在许多领域推广 美国刑事司法人口中 OUD 比率较高。